Q-omics provides the consensus-scored RELL2 profile across patient tissues and cancer cell-line models. RELL2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RELL2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RELL2 RNA expression shows 18,411 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where RELL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RELL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RELL2 survival associations across molecular data types. RELL2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RELL2 RNA expression–survival associations across cancer types. High RELL2 expression shows unfavorable associations in KIRC, UVM, ACC, LGG and KICH, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RELL2 RNA expression.
This table summarizes RELL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RELL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RELL2 shows higher tumor expression in HNSC, COAD, BLCA, STAD, LIHC and KIRP. The HNSC box plot shows higher RELL2 RNA expression in tumor versus normal tissue (log2 FC = +0.960, t-test p < 0.001).
This table shows molecular features associated with RELL2 in patient tissues and cancer cell lines. In patient samples, RELL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RELL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
